Completed PHASE4 INTERVENTIONAL 2-arm
NCT00677300
Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients (RADAR)
Evaluation of Safety and Efficacy of Raltegravir/Darunavir Combination in Antiretroviral-Naive Patients
Sponsor: Dallas VA Medical Center
Conditions
HIV Infections
Interventions
Darunavir Raltegravir Ritonavir Tenofovir/Emtricitabine
Updated 1 time since 2024 Last updated: Sep 5, 2014 Started: Jan 31, 2009 Primary completion: Oct 31, 2012 Completion: Dec 31, 2012
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT00677300, this PHASE4 trial focuses on HIV Infections and remains completed. Sponsored by Dallas VA Medical Center, it has been updated 1 time since 2009, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
1 version recorded Completed — PHASE4
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Dallas VA Medical Center
- Merck Sharp & Dohme LLC
- Tibotec Pharmaceutical Limited
Data source: Dallas VA Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .